---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Complement c5 inhibitors"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Complement c5 inhibitors. Topics: Avacincaptad pegol: mechanism; Avacincaptad pegol: indication, dosage, and contraindications; Avacincaptad pegol: neovascular AMD and intraocular pressure warnings; GATHER1 and GATHER2: design; 6 further topics. 10 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/complement-c5-inhibitors"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Complement c5 inhibitors

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Complement C5 Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

### Avacincaptad pegol: mechanism

> “Avacincaptad pegol (ACP) is a pegylated RNA aptamer that inhibits complement C5.”

Source: [Khanani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41407269/)

<a id="topic-2.2.2.1.4-2"></a>

### Avacincaptad pegol: indication, dosage, and contraindications

> “Initial U.S. Approval: 2023”
> “IZERVAY® is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “The recommended dosage for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days).”
> “IZERVAY is contraindicated in patients with active intraocular inflammation.”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### Avacincaptad pegol: neovascular AMD and intraocular pressure warnings

> “In the GATHER1 and GATHER2 clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12.”
> “Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group.”
> “Patients receiving IZERVAY should be monitored for signs of neovascular AMD.”
> “Transient increases in intraocular pressure (IOP) have been observed after an intravitreal injection, including with IZERVAY”
> “The most common adverse reactions (incidence ≥ 5%) were conjunctival hemorrhage, increased IOP, blurred vision, neovascular age-related macular degeneration, punctate keratitis, and eye pain”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-4"></a>

### GATHER1 and GATHER2: design

> “The safety and efficacy of IZERVAY were demonstrated in two randomized, multi-center, double-masked, sham-controlled, 18- and 24-month studies (GATHER1-NCT02686658 and GATHER2-NCT04435366, respectively) in patients with GA due to AMD.”
> “Patients receiving monthly IZERVAY were re-randomized at Month 12 to receive either IZERVAY monthly (EM) or every other month (EOM).”
> “At any time during the GATHER2 study, patients that developed choroidal neovascularization were concomitantly treated with anti-VEGF therapy.”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

### GATHER1 and GATHER2: GA growth with monthly dosing

| Study and time point | Avacincaptad pegol, N | Sham, N | GA rate of growth, avacincaptad pegol (mm2/year) | GA rate of growth, sham (mm2/year) | Difference (95% CI) (mm2/year) | Difference % | p value |
| --- | --- | --- | --- | --- | --- | --- | --- |
| GATHER1, month 12 | “N=67” | “N=110” | “1.22” | “1.89” | “0.67 (0.21-1.13)” | “35%” | “<0.01” |
| GATHER2, month 12 | “N=225” | “N=222” | “1.75” | “2.12” | “0.38 (0.12-0.63)” | “18%” | “<0.01” |
| GATHER2, month 24 (monthly in both years) | “N=96” | “N=203” | “2.23” | “2.59” | “0.36 (0.07 – 0.66)” | “14%” | “0.0165” |

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

> “Over a 12-month period, there was a statistically significant reduction of the rate of GA growth (0.05 mm/year; p<0.01 with square root transformed data) in patients treated with IZERVAY EM compared to sham.”
> “In the treatment arm that included patients who received IZERVAY EM treatment for one year and EOM treatment for the second year, the annualized rate of GA growth was 2.10 mm2/year.”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### GATHER1: phase 2/3 primary endpoint

> “A total of 286 participants with GA secondary to AMD.”
> “The reduction in the mean rate of GA growth (square root transformation) over 12 months was 27.4% (P = 0.0072) for the avacincaptad pegol 2 mg cohort and 27.8% (P = 0.0051) for the avacincaptad pegol 4 mg cohort compared with their corresponding sham cohorts.”

Source: [Jaffe et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32882310/)

<a id="topic-2.2.2.1.4-7"></a>

### GATHER2: 12-month primary endpoint and safety

> “To be eligible, patients had to be aged 50 years or older with non-centrepoint-involving geographic atrophy and best corrected visual acuity between 20/25 and 20/320 in the study eye.”
> “Between June 22, 2020, and July 23, 2021, 1422 patients were screened for eligibility, of whom 448 were enrolled and randomly assigned to avacincaptad pegol 2 mg (n=225) or sham (n=223).”
> “representing a 14% difference between the avacincaptad pegol 2 mg group and the sham group”
> “There were no endophthalmitis, intraocular inflammation, or ischaemic optic neuropathy events over 12 months.”
> “To month 12, macular neovascularisation in the study eye occurred in 15 (7%) patients in the avacincaptad pegol 2 mg group and nine (4%) in the sham group, with exudative macular neovascularisation occurring in 11 (5%) in the avacincaptad pegol 2 mg group and seven (3%) in the sham group.”

Source: [Khanani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37696275/)

<a id="topic-2.2.2.1.4-8"></a>

### GATHER2: two-year results

> “Overall, 175 and 184 patients in the ACP and sham group completed the study at year 2, respectively.”
> “From baseline to year 2, the mean rate of GA area growth was 4.46 mm2 (standard error [SE], 0.25 mm2) with ACP EM and 5.18 mm2 (SE, 0.17 mm2) with sham, a difference in growth of 0.724 mm2 (95% confidence interval [CI], 0.133-1.315 mm2; P = 0.0165), representing a 14% difference.”
> “The incidence of choroidal neovascularization (study eye) was 11.6% with ACP (all treated) versus 9.0% with sham over 2 years.”
> “No events of retinal vasculitis, ischemic optic neuropathy, or serious intraocular inflammation occurred over 2 years.”

Source: [Khanani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41407269/)

<a id="topic-2.2.2.1.4-9"></a>

### GATHER2: guideline summary of lesion growth reductions

> “GATHER2 was a phase 3 clinical trial with 448 study participants with foveal-sparing GA.”
> “At 12 months, square-root-transformed GA area growth rate was reduced by 14% in treated eyes versus sham.”
> “For patients treated monthly in the first 12 months, followed by EOM for months 13 to 24, there was a 19% reduction in mean GA growth rate at month 24.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.4-10"></a>

### GATHER1 and GATHER2: post hoc analysis of vision loss

> “A post hoc analysis of 12-month data for pooled ACP 2 mg and sham groups is reported.”
> “Lower proportions of study eyes experienced ≥10-, ≥15-, or ≥20-BCVA letter loss from baseline over 12 months with ACP 2 mg (11.6%, 4.0%, and 1.6%, respectively) versus sham (14.1%, 7.6%, and 4.5%, respectively).”
> “There was a reduction in the risk of persistent loss of ≥15 BCVA ETDRS letters with ACP 2 mg (3.4%) versus sham (7.8%) through 12 months.”

Source: [Danzig et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38719191/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
